Noubar Afeyan, Director at Moderna, Inc. (MRNA), sold 29,100 shares at $145.57 ($4.3M) on 2024-06-12, disclosed to the SEC on 2024-06-14.
Scheduled sale ($4.3M) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $142.97 | 700 | $100K | 2.3% |
| 2 | $144.46 | 408 | $59K | 1.4% |
| 3 | $144.46 | 408 | $59K | 1.4% |
| 4 | $145.57 | 1,263 | $184K | 4.3% |
| 5 | $145.57 | 1,263 | $184K | 4.3% |
| 6 | $146.55 | 3,031 |
| $444K |
| 10.4% |
| 7 | $146.55 | 3,031 | $444K | 10.4% |
| 8 | $147.55 | 6,397 | $944K | 22.0% |
| 9 | $147.55 | 6,397 | $944K | 22.0% |
| 10 | $148.61 | 1,601 | $238K | 5.6% |
| 11 | $148.61 | 1,601 | $238K | 5.6% |
| 12 | $149.39 | 1,400 | $209K | 4.9% |
| 13 | $149.39 | 1,400 | $209K | 4.9% |
| 14 | $150.24 | 200 | $30K | 0.7% |
| Total | $147.29 avg | 29,100 | $4.3M | 100% |
| Filing → |
| MRNA | SELL | 2025-12-15 | $1.4M | — | Filing → |
| MRNA | SELL | 2024-08-02 | $3.6M | — | Filing → |
| MRNA | SELL | 2024-07-26 | $2.9M | — | Filing → |